Nuvation Bio (NYSE:NUVB) Issues Earnings Results

Nuvation Bio (NYSE:NUVB) posted its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12), FiscalAI reports. The firm had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $34.39 million. Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 43.15%.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI sales and market position strengthened: U.S. net product revenue rose 18% sequentially to $27.5 million, and the company said IBTROZI led the market in active patients and held more than 60% of first-line new patient starts.
• The overall ROS1 TKI market saw a roughly 15% decline in new patient starts during the quarter, while management noted that the pool of patients switching from older therapies is shrinking. Nuvation said future growth increasingly depends on first-line adoption, better testing, and converting patients to targeted treatment.
• Safusidenib advanced toward potential near-term data: The company cited encouraging long-term Phase II results and FDA Fast Track designation, and expects initial response data from two studies could emerge in 2027; randomized studies with progression-free survival endpoints are expected to take longer, potentially until 2029 or beyond.
• Nuvation reported $663.4 million in cash, cash equivalents, and marketable securities and said it believes it has sufficient capital to reach profitability. Management said IBTROZI’s quarterly revenue run rate now covers its launch-related expenses on a standalone basis, while operating expenses were $75.2 million for the quarter.

Nuvation Bio Trading Down 10.0%

NUVB opened at $4.26 on Friday. Nuvation Bio has a fifty-two week low of $4.05 and a fifty-two week high of $9.75. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.37 and a quick ratio of 8.14. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -10.64 and a beta of 1.73. The company’s 50 day moving average price is $5.44 and its two-hundred day moving average price is $5.38.

Insider Transactions at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.09, for a total transaction of $709,000.00. Following the completion of the transaction, the insider owned 100,000 shares of the company’s stock, valued at approximately $709,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 30.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NUVB. B. Riley Financial reiterated a “buy” rating on shares of Nuvation Bio in a research note on Friday, August 7th. Cantor Fitzgerald began coverage on Nuvation Bio in a research report on Friday, August 21st. They set an “overweight” rating on the stock. HC Wainwright boosted their price objective on Nuvation Bio from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Wall Street Zen cut Nuvation Bio from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Wednesday, September 16th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Nuvation Bio currently has an average rating of “Moderate Buy” and an average price target of $12.89.

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.